Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 62Prostatic Neoplasms 35Kidney Neoplasms 18Carcinoma, Transitional Cell 17Melanoma 15Urinary Bladder Neoplasms 14Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Clear-cell metastatic renal cell carcinoma 11Colorectal Neoplasms 9Neoplasms 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Pancreatic Neoplasms 5Urogenital Neoplasms 4Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Urethral Neoplasms 3Penile Neoplasms 3Neuroblastoma 3Liver Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Ureteral Neoplasms 2

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone-Sensitive Prostate Cancer × Ipilimumab × Genitourinary × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡